SCHEMBL20173743

SCHEMBL20173743

COC(=O)c1ccc(C(C)C)cc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 4/20 0.48
NOTUM Q6P988 2/20 0.44
AKR1C3 P42330 4/20 0.41
AKR1C2 P52895 4/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK4 Q16654 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CES2 O00748 1/20 0.40
AKR1C4 P17516 1/20 0.40
AKR1C1 Q04828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12089913 0.83 AKR1C3 (0.46) AKR1C3AKR1C2KDM4EALDH1A1CES2
SCHEMBL20178592 0.81 CFTR (0.43) CFTRNOTUMAKR1C3AKR1C2KDM4E
SCHEMBL5461078 0.81 CES2 (0.42) AKR1C3AKR1C2ALDH1A1CES2GAA
SCHEMBL21090566 0.80 CA12 (0.47) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL20178581 0.79 THRA (0.41) CFTRNOTUMKDM4EALDH1A1HPGD
SCHEMBL1940800 0.79 CA12 (0.61) CFTRNOTUMKDM4EALDH1A1MAPT
SCHEMBL2002005 0.79 CFTR (0.69) CFTRNOTUMKDM4EALDH1A1MAPT
SCHEMBL13948877 0.79 CFTR (0.51) CFTRNOTUMKDM4EALDH1A1MAPT
SCHEMBL695717 0.79 CFTR (0.51) CFTRNOTUMKDM4EALDH1A1MAPT
SCHEMBL7220810 0.79 MAPT (0.47) CFTRKDM4EALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 CFTR 32/4885NOTUM 1474/4885AKR1C3 1156/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 CFTR 32/4885NOTUM 1474/4885AKR1C3 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.